
Association Between Ki67 After Neoadjuvant Chemotherapy and Disease-Free Survival in Breast Cancer.
Author(s) -
Aan Wahyu Setiawan,
Mulawan Umar,
Erial Bahar
Publication year - 2021
Publication title -
sriwijaya journal of surgery
Language(s) - English
Resource type - Journals
ISSN - 2722-3558
DOI - 10.37275/sjs.v4i2.57
Subject(s) - breast cancer , medicine , chemotherapy , oncology , breast carcinoma , retrospective cohort study , neoadjuvant therapy , cancer , stage (stratigraphy) , disease , paleontology , biology
Background: Post Chemotherapy Ki67 in recent year has been investigated as a predictive and prognostic factor in locally advanced breast cancer patient undergoing neoadjuvant chemotherapy.
Objectives: To describe the relationship between post-chemotherapy Ki67 and disease-free survival after neoadjuvant chemotherapy in patients with locally advanced breast cancer at Dr. Hospital. Mohammad Hoesin Palembang.
Methods: This study is an analytical observational study with prognostic test design conducted in 30 stage III B breast cancer patient. A retrospective search of a prospectively maintained clinical database was performed to identify patient treated with neoadjuvant chemotherapy at the Mohammad Hoesin Hospital. The expression of Ki67 was assessed using immunohisto-chemistry in post therapy surgical excision specimen.
Results: From 30 patients, there was a significant relationship between Post Chemotherapy Ki67 and disease- free survival in patients with locally advanced breast cancer (r = -0,742, p = 0.000). The cut off point value of Ki67 was 27,5% with an area under curve (AUC) of 0,716. The results of the post-chemotherapy Ki67 prognosis test included sensitivity 64%, specificity 60%, Positive Predictive Value 88,9%, Negative Predictive Value 25%, accuracy 63,3%.
Conclusion: There is a significant relationship between Post Chemotherapy Ki67 to disease free survival and Post Chemotherapy Ki67 can be used as a prognostic biomarker in breast carcinoma patients undergoing neoadjuvant chemotherapy.